Reinforcement Learning with Action-Derived Rewards for Chemotherapy and Clinical Trial Dosing Regimen Selection
By Gregory Yauney, Pratik Shah. 2018
80 citations recorded by the source corpus.
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
- Chao Yu
- Shimon Whiteson
- Sergey Levine
- Chelsea Finn
- Katja Hofmann
- Jiming Liu
- Luisa M. Zintgraf
- Yarin Gal
Citations in the corpus
- Reinforcement Learning in Healthcare: A Survey (2019, methodology): “cal or generic cancer clinical trial Goldberg & Kosorok [96], Soliman [97] Q-learning N/A N/A Linear model Addressing problems with censored data and a flexible number of stages. Yauney & Shah [98] Q-learning N/A DRL (Double DQN) ODE model Addressing the problem of unstructured outcome reward”
- Artificial Intelligence for Clinical Trial Design. (2019, methodology): “In a previous study, Shah et al. evaluated the significance and efficacy of clinical evidence generated from advanced technology-enabled non-invasive diagnostic screening (TES) using low-cost 584 Trends in Pharmacological Sciences, August 2019, Vol. 40, No. 8 smartphones and other point-of-care medi”
- VariBAD: A Very Good Method for Bayes-Adaptive Deep RL via Meta-Learning (2019, background): “Balancing this trade-off is key to maximising expected return during learning, which is desirable in many settings, particularly in high-stakes real-world applications like healthcare and education (Liu et al., 2014; Yauney & Shah, 2018).”
- Artificial intelligence in cancer target identification and drug discovery (2022, methodology): “For example, Shah et al 261 construct an arti fi cial intelligence system that made use of the ‘ self-learning ’ deep reinforcement learning technology to looks at treatment regimens currently in use, and iteratively adjusts the doses.”
- ARTIFICIAL INTELLIGENCE AND PERSONALIZED MEDICINE (2019, background): “AI can be exploited in relevant large scale population trials that seek to minimize the deployment and use of inappropriate drugs or interventions studies for each participant in the trial, as described recently by Yauney and Shah.[39] Of great interest in this context are the design and conduct of ”